Altogether, we found that activated donor NK cells efficiently eliminate CML-BC cells, with TKI resistance in the absence or presence of BCR-ABL1 mutations, and preferentially target the LSC-containing CD34+CD38− subset, a potential source of disease relapse. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.